

Curriculum Vitae

Personal information **Laure BADUEL**

Work experience

1. Employer: Anses ANMV
 - Start date: 012020
 - End date:
 - Position: Project manager
 - Activities: Management of transversal projects, notably in relation with veterinary professional organisations, therapeutic gaps and big data.
 - Country: France
2. Employer: ANSES ANMV
 - Start date: 122015
 - End date: 012020
 - Position: Head of Pharmaceuticals assessment Unit
 - Activities: Management of FR Veterinary Pharmaceuticals Assessment Unit
 - Country: France
3. Employer: BIMEDA France
 - Start date: 012014
 - End date: 122015
 - Position: Qualified Person _ Regulatory Affairs
 - Activities: Regulatory Affairs _ Pharmaceutical Responsible _ QA _ Technical support
 - Country: France
4. Employer: ITG Consulting
 - Start date: 092011
 - End date: 122013
 - Position: Consultant
 - Activities: Consulting in Clinical development for Ceva Santé Animale and in Pharmaceuticals Regulatory for Provimi Santé Animale
 - Country: France
5. Employer: CEVA Santé Animale
 - Start date: 092006
 - End date: 082011
 - Position: Head of Preclinical and Clinical Development
 - Activities: Management of 4 units (25 persons): Clinical Development, Preclinical Development, Biostatistics, Exploratory
 - Country: France
6. Employer: BAYER Animal Health
 - Start date: 092003
 - End date: 082006
 - Position: Head of Clinical Development and Regulatory Affairs
 - Activities: Management of Clinical Development and Regulatory Affairs team Pharmaceutical Responsible, QA manager HSE Responsible
 - Country: France
7. Employer: NOVARTIS Animal Health
 - Start date: 051988
 - End date: 082003
 - Position: Head of Clinical development and Regulatory Affairs
 - Activities: Management of Clinical Development and Regulatory Affairs team (1998_2003) Clinical Development Project Manager (1988_1998)
 - Country: France

Education and training

1. Subject: Ecole Nationale Vétérinaire Toulouse
 - Start date: 091983
 - End date: 071987
 - Qualification: Doctor in Veterinary Medicine
 - Organisation: Veterinary medicine
 - Country: France

Additional information

Publications

Règlementation du médicament vétérinaire : quel impact sur l'arsenal thérapeutique à la disposition du praticien, en termes de disponibilité et d'innovation ? *Bull. Acad. Vét.* 2024; 1-9
doi.org/10.3406/bavf.2024.71091

Procedure withdrawals within Europe: past trends, impact and communication recommendations *TOPRA J.* 2022 (Vo)

Impact du traitement par les biocides des eaux d'abreuvement des porcs, des volailles et des lapins sur la stabilité des antibiotiques	<i>Bulletin C</i> 2019 (96)
Evolutions des temps d'attente dans le cadre de l'AMM : motivations et impacts	<i>Bulletin C</i> 2019 (95)
Médicaments vétérinaires pour les abeilles : avantages et obligations (Partie 1 et Partie 2)	<i>La Santé</i> 2018 (284) 191-197
Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study	<i>J Vet Inte</i> 2013
Efficacy of permethrin, dinotefuran and pyriproxyfen on adult fleas, flea eggs collection, and flea egg development following transplantation of mature female fleas (<i>Ctenocephalides felis felis</i>) from cats to dogs	<i>J Veterin</i> (190) 541
Efficacy of dinotefuran, permethrin and pyriproxyfen combination spot-on against <i>Aedes aegypti</i> mosquitoes on dogs	<i>J Veterin</i> 2012 (189)
Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease	<i>J Vet Inte</i> 2010; 24,
Determination of a dosage regimen of colistin by pharmacokinetic / pharmacodynamic integration and modeling for treatment of G.I.T. disease in pigs	<i>Res Vet S</i> 2009; 88(
Efficacy of phoxim 50%E.C. (ByeMite®) for treatment of <i>Dermanyssus gallinae</i> in laying hens under field conditions	<i>Revue Me</i> 2006, 157
Long term tolerability of benazepril in dogs with congestive heart failure	<i>J Vet Car</i> 2004; 6: 7
The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double blinded, placebo-controlled, long-term clinical trial	<i>J Vet Car</i> 1999; 1: 7
Prophylaxis of natural <i>Fasciola hepatica</i> infection in cattle with triclabendazole	<i>Revue Me</i> 1995, 146
Assessment of triclabendazole activity in ovine <i>Fasciola hepatica</i> infestation under field conditions	<i>Bulletin C</i> 1990-2-O
Proposals for justificative criterions on the existence of residues studies in pharmaco-toxicology expert evaluations	<i>Revue Me</i> 1990,141

Projects

Participation to the Development and registration of several VMP, notably :FORTEKOR, CLOMICALM, ATOPICA, MILBEMAX, ADVANTIX, ADVOCATE, PROFENDER, PRILACTONE, VELACTIS, VECTRA D

Memberships

Nominated in december 2024 as Corresponding member in the Clinical Sciences Section at the Académie Vétérinaire de France

Other Relevant Information